Proactiveinvestors recommends

Red Sky Energy sees upside potential as New South Wales decision on Talma CSG pilot draws near
Xceed Resources: Cash backed and developing coal production and cash flows from Moabsvelden
Oro Verde on the exploration trail of gold and copper in Chile, commences trading today

Additional Information

Market:	ASX
Sector:	Aerospace
EPIC:	HTX
Latest Price:	0.01 (-9.09% )
52-week High:	0.08
52-week Low:	0.01
Market Cap:	2.18M

1 year chart

1 day chart

HealthLinx

HealthLinx (ASX: HTX) is an emerging biomarker and diagnostic company with an integrated platform in biomarker and bioactive peptide discovery platforms.

The company develops novel, non-invasive, serum-based, diagnostic products.

HealthLinx opens up key UK market for its OvPlex™ Ovarian Cancer Diagnostic

Wednesday, December 02, 2009

Victorian-based diagnostics company HealthLinx (ASX: HTX) has taken a big step forward forging a key second market for its ovarian cancer diagnostic OvPlex™ in the UK.

The market responded to the announcement, pushing the HelathLinx share price up 17.6%, to $0.10.

United Kingdom Distributor Intus Healthcare has completed a commercial arrangement with major hospital and healthcare services group Spire Healthcare to process and market OvPlex™ in the UK from February 2010.

Market potential for OvPlex™ in the UK is greater than 750,000 units.

In a statement, the company said OvPlex™ is the most accurate commercially-available ovarian cancer diagnostic. The diagnostic is based on a simple blood test that women can request from their doctors." The launch in the UK is the first time the OvPlex™ diagnostic will be available outside Australia.

Nick Gatsios managing director of HelathLinx said “This is the next step in the global roll-out of OvPlex™ and we are confident that OvPlex™ is a best in market ovarian cancer diagnostic, as are our distribution partners. "

The company continues to deliver on its milestones and we believe commercial markets will respond positively to this latest achievement” says Mr Nick Gatsios, Managing Director of HealthLinx.

Spire Healthcare is the second largest private hospital group in the UK, with a network of 36 hospitals nationwide.

The group offers a range of services including pathology, diagnostic tests and investigations as well as the latest surgical procedures. The OvPlex™ test will be made available through its hospitals throughout England, Scotland and Wales.

Worldwide over 240,000 new cases of ovarian cancer are diagnosed each year while more than 130,000 women die from the disease. The UK region accounts for over 7,000 of these diagnoses and 4,000 lives lost every year.

Meanwhile, HealthLinx is continuing research and development on its next generation ovarian cancer diagnostic to further improve accuracy and earlier detection.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.